Response gene to complement 32 (RGC-32) in endothelial cells is induced by glucose and helpful to maintain glucose homeostasis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 9, 2014, Pages 2541-2549

  Guo, Shuzhen ^a,b   Philbrick, Melissa J ^b   An, Xiaojing ^b   Xu, Ming ^b   Wu, Jiaping ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endothelial cells; Glucose homeostasis; The response gene to complement 32

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOGENESIS INHIBITOR; COMPLEMENT; COMPLEMENTARY DNA; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 12; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE 1; GREEN FLUORESCENT PROTEIN; I KAPPA B; INSULIN; RESPONSE GENE TO COMPLEMENT 32; SMALL INTERFERING RNA; SOLUTE CARRIER FAMILY 2 FACILITATED GLUCOSE TRANSPORTER MEMBER 12; UNCLASSIFIED DRUG; WEDELOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; DENSITOMETRY; DNA MICROARRAY; DNA SEQUENCE; ENDOTHELIAL DYSFUNCTION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOBLOTTING; INSULIN SENSITIVITY; LIPID DIET; METABOLIC REGULATION; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; VASOMOTOR DISORDER;

EID: 84907856084     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cleaver O and Melton DA. Endothelial signaling during development. Nat Med 2003; 9: 661-668.
2. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G and Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
3. Meigs JB, Hu FB, Rifai N and Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-1986.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
5. Vlaicu SI, Tegla CA, Cudrici CD, Danoff J, Madani H, Sugarman A, Niculescu F, Mircea PA, Rus V and Rus H. Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res 2013; 56: 109-121.
6. Zhu L, Qin H, Li PY, Xu SN, Pang HF, Zhao HZ, Li DM and Zhao Q. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res 2012; 31: 29.
7. Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, Rus V, Chen H, Mircea PA, Shamsuddin A and Rus H. Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol 2010; 88: 67-76.
8. Tegla CA, Cudrici CD, Azimzadeh P, Singh AK, Trippe R, Khan A, Chen H, Andrian-Albescu M, Royal W, Bever C, Rus V and Rus H. Dual role of Response gene to complement-32 in multiple sclerosis. Exp Mol Pathol 2013; 94: 17-28.
9. Li Z, Xie WB, Escano CS, Asico LD, Xie Q, Jose PA and Chen SY. Response gene to complement 32 is essential for fibroblast activation in renal fibrosis. J Biol Chem 2011; 286: 41323-41330.
10. Wang JN, Shi N, Xie WB, Guo X and Chen SY. Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration. Arterioscler Thromb Vasc Biol 2011; 31: e19-26.
11. An X, Jin Y, Guo H, Foo SY, Cully BL, Wu J, Zeng H, Rosenzweig A and Li J. Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor. Circulation 2009; 120: 617-627.
12. Cui XB, Guo X and Chen SY. Response gene to complement 32 deficiency causes impaired placental angiogenesis in mice. Cardiovasc Res 2013; 99: 632-639.
13. Van Gaal LF, Mertens IL and De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
14. Sena CM, Pereira AM and Seica R. Endothelial dysfunction-a major mediator of diabetic vascular disease. Biochim Biophys Acta 2013; 1832: 2216-2231.
15. Jin Y, Wu J, Song X, Song Q, Cully BL, Messmer-Blust A, Xu M, Foo SY, Rosenzweig A and Li J. RTEF-1, an upstream gene of hypoxia-inducible factor-1alpha, accelerates recovery from ischemia. J Biol Chem 2011; 286: 22699-22705.
16. Messmer-Blust AF, Philbrick MJ, Guo S, Wu J, He P and Li J. RTEF-1 attenuates blood glucose levels by regulating insulin-like growth factor binding protein-1 in the endothelium. Circ Res 2012; 111: 991-1001.
17. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, Michel T and Plutzky J. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 2009; 119: 110-124.
18. McClain DA. Hexosamines as mediators of nutrient sensing and regulation in diabetes. J Diabetes Complications 2002; 16: 72-80.
19. Hebert LF Jr, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, Neidigh JL, Zhu JS, Baron AD and McClain DA. Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest 1996; 98: 930-936.
20. Nakaishi Y, Bando M, Shimizu H, Watanabe K, Goto F, Tsuge H, Kondo K and Komatsu M. Structural analysis of human glutamine: fructose-6-phosphate amidotransferase, a key regulator in type 2 diabetes. FEBS Lett 2009; 583: 163-167.
21. Purcell SH, Aerni-Flessner LB, Willcockson AR, Diggs-Andrews KA, Fisher SJ and Moley KH. Improved insulin sensitivity by GLUT12 overexpression in mice. Diabetes 2011; 60: 1478-1482.
22. Waller AP, George M, Kalyanasundaram A, Kang C, Periasamy M, Hu K and Lacombe VA. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. Biochim Biophys Acta 2013; 1832: 121-127.
23. de Heer J, Pedersen J, Orskov C and Holst JJ. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 2007; 50: 2135-2142.
24. Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B and Holst JJ. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006; 130: 44-54.
25. Bahrami J, Longuet C, Baggio LL, Li K and Drucker DJ. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 2010; 139: 857-868.